Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (151-160 of 209) with videos related to

Pageof 21
Sort By:
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
The Journal of Urology|June 24, 2020
Reply by AuthorsDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
BJU International|November 19, 2016
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative studyAmishi Y Shah, Jose A Karam, Gabriel G Malouf, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaLucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.
Pageof 21

Showing results (151-160 of 209) with videos related to

Sort By:
Pageof 21
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
The Journal of Urology|June 24, 2020
Reply by AuthorsDaniel M Geynisman, Brian T Kadow, Brian M Shuch, et al.
Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
BJU International|November 19, 2016
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative studyAmishi Y Shah, Jose A Karam, Gabriel G Malouf, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaLucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.
Pageof 21